ELHT Evidence Hub
  • HOME
  • FOCUS ON YOUR SPECIALTY OR PROFESSION
  • STUDY SKILLS
  • FICTION, LEISURE AND SELF-HELP

Management of sulfonylurea-treated monogenic diabetes in pregnancy: Implications of placental glibenclamide transfer

3/4/2017

0 Comments

 
Author(s): Shepherd M.; Brook A.J.; Chakera A.J.; Hattersley A.T.

Source: Diabetic Medicine; 2017

Available in full text at Diabetic Medicine -  from John Wiley and Sons

Abstract:The optimum treatment for HNF1A/HNF4A maturity-onset diabetes of the young and ATP-sensitive potassium (KATP) channel neonatal diabetes, outside pregnancy, is sulfonylureas, but there is little evidence regarding the most appropriate treatment during pregnancy. Glibenclamide has been widely used in the treatment of gestational diabetes, but recent data have established that glibenclamide crosses the placenta and increases risk of macrosomia and neonatal hypoglycaemia. This raises questions about its use in pregnancy. We review the available evidence and make recommendations for the management of monogenic diabetes in pregnancy. Due to the risk of stimulating increased insulin secretion in utero, we recommend that in women with HNF1A/ HNF4A maturity-onset diabetes of the young, those with good glycaemic control who are on a sulfonylurea per conception either transfer to insulin before conception (at the risk of a short-term deterioration of glycaemic control) or continue with sulfonylurea (glibenclamide) treatment in the first trimester and transfer to insulin in the second trimester. Early delivery is needed if the fetus inherits an HNF4A mutation from either parent because increased insulin secretion results in ~800-g weight gain in utero, and prolonged severe neonatal hypoglycaemia can occur post-delivery. If the fetus inherits a KATP neonatal diabetes mutation from their mother they have greatly reduced insulin secretion in utero that reduces fetal growth by ~900 g. Treating the mother with glibenclamide in the third trimester treats the affected fetus in utero, normalising fetal growth, but is not desirable, especially in the high doses used in this condition, if the fetus is unaffected. Prospective studies of pregnancy in monogenic diabetes are needed.Copyright © 2017 Diabetes UK.
​
Database: EMBASE
0 Comments



Leave a Reply.

    The following databases were searched:
    EMBASE,  MEDLINE, PsycINFO, BNI, CINAHL, 
    to find  ELHT staff publications

    Specialties

    All
    ANAESTHETICS
    CARDIOLOGY
    CRITICAL CARE
    DERMATOLOGY
    DIABETES
    ELDERLY CARE
    EMERGENCY CARE
    GASTROENTEROLOGY
    GYNAECOLOGY
    JUNIOR DOCTORS
    MAXILLOFACIAL
    NEONATOLOGY
    NEUROLOGY
    NURSING
    OBSTETRICS
    ONCOLOGY
    OPHTHALMOLOGY
    ORTHOPAEDICS
    PAEDIATRICS
    PATHOLOGY
    PHYSIOTHERAPY
    RADIOLOGY
    RENAL
    RESPIRATORY
    RHEUMATOLOGY
    STROKE
    SURGERY
    UROLOGY
    VASCULAR SURGERY

    RSS Feed

    Archives - past 2 years

    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017

Picture
Contact us
Picture
Support
Picture
Feedback
Picture
Performance
Picture
Catalogue
Picture
News
Picture
OpenAthens
Picture
Search
Picture
Privacy Policy
Connect with us
Picture
Picture
Picture